Showing results (21-30 of 38) with videos related to
Sort By:
Pageof 4
Thyroid : Official Journal of the American Thyroid Association|September 29, 2005
Long-term environmental exposure to perchlorate through drinking water and thyroid function during pregnancy and the neonatal periodRafael Téllez Téllez, Patricio Michaud Chacón, Carlos Reyes Abarca, et al.Current Drug Metabolism|December 20, 2003
Reaction phenotyping in drug discovery: moving forward with confidence?J Andrew Williams, Susan I Hurst, Jonathan Bauman, et al.Clinical Pharmacokinetics|January 19, 2011
Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human predictionJennifer Q Dong, David H Salinger, Christopher J Endres, et al.Clinical Pharmacology in Drug Development|January 25, 2019
Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and SafetyEdward Lee, John P Gibbs, Maurice G Emery, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancerWilliam P Petros, Gloria Broadwater, Donald Berry, et al.The Journal of Clinical Endocrinology and Metabolism|December 2, 2004
The effect of perchlorate, thiocyanate, and nitrate on thyroid function in workers exposed to perchlorate long-termLewis E Braverman, XueMei He, Sam Pino, et al.Journal of Clinical Pharmacology|November 19, 2016
Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)John P Gibbs, Sameer Doshi, Mita Kuchimanchi, et al.Journal of Clinical Pharmacology|September 27, 2016
Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic ImpairmentJohn P Gibbs, J Greg Slatter, Ogo Egbuna, et al.Journal of Cardiovascular Pharmacology and Therapeutics|May 18, 2018
Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment ImplicationsScott M Wasserman, Marc S Sabatine, Michael J Koren, et al.Journal of Clinical Pharmacology|July 29, 2010
Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitorJohn P Gibbs, Maurice G Emery, Ian McCaffery, et al.Pageof 4